title: Percutaneous parathyroid ethanol ablation in patients with multiple endocrine neoplasia type 1.
abstract: OBJECTIVE
  The objective of our study was to show the efficacy and safety of percutaneous ethanol ablation in managing recurrent primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1 (MEN1) after subtotal parathyroidectomy.
  
  
  CONCLUSIONS
  Ethanol ablation is a viable alternative to reoperation for the management of recurrent primary hyperparathyroidism in patients with MEN1.
authors.affiliation: Department of Radiology, Mayo Clinic, 200 1st St., SW, Rochester, MN 55902, USA.
authors.forename: Mark W
authors.initials: MW
authors.lastname: Veldman
authors.forename: Carl C
authors.initials: CC
authors.lastname: Reading
authors.forename: Michael A
authors.initials: MA
authors.lastname: Farrell
authors.forename: Brian P
authors.initials: BP
authors.lastname: Mullan
authors.forename: Robert A
authors.initials: RA
authors.lastname: Wermers
authors.forename: Clive S
authors.initials: CS
authors.lastname: Grant
authors.forename: Geoff B
authors.initials: GB
authors.lastname: Thompson
mesh_terms: D000328:Adult; D000368:Aged; D000431:Ethanol / Q000008:administration & dosage*; D006801:Humans; D006961:Hyperparathyroidism / Q000628:therapy*; D007279:Injections, Subcutaneous; D008875:Middle Aged; D018761:Multiple Endocrine Neoplasia Type 1 / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D010282:Parathyroid Neoplasms / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000431:Ethanol